Quo vadis, biotech? (Part 2).
Those following the financial markets and the valuation of biotechnology companies recently might find themselves perplexed. Towards the end of 1999, during which the availability of capital for biotech initial public offerings and for private investment rounds seemingly withered, the markets suddenly turned around and gave the biotechnology industry its biggest bonanza ever.
Drews
J
J
International Biomedicine Management Partners, Basel Switzerland and Managing Partner, Bear Stearns Health Innoventures, New York, NY, USA